Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Scientists attribute breast cancer decline to publicity surrounding WHI results

Between 2002 and 2003, American women experienced a 7 percent decline in breast cancer incidence, which scientists attribute to the publicity surrounding results of the Women's Health Initiative (WHI).

8 Dec 2009

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

BMI and waist circumference explain one half of all fatal and one quarter of all non-fatal cardiovascular disease in those overweight and obese in ten-year follow-up study

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Study suggests sustained health risks linked to adverse childhood experiences

Research from the Institute of Psychiatry at King's College London has found that negative experiences in childhood may alter not only mental health but also physical health, into middle age and beyond.

8 Dec 2009

Discovery presents a vital step towards efficient treatment of vascular injuries

Hyperglycemia starts a complex chain of events that damages blood vessels and cause cardiovascular disease. Scientists at Lund University Diabetes Centre (LUDC) have now been able to demonstrate why this happens, as well as how the destructive chain can be broken.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

VAI expands to support annual research operation

On December 8, Van Andel Institute (VAI) cuts the ribbon on its eight-story, $178 million, 240,000 square foot Phase II expansion. The expanded facility creates economic and scientific opportunity both for VAI and West Michigan's burgeoning life sciences sector and adds to the more than $1 billion investment in infrastructure already in place along Grand Rapids' Medical Mile.

7 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.

6 Dec 2009

Chicken pox vaccine also reduces risk of herpes zoster in children

Herpes zoster, also known as shingles, is very rare among children who have been vaccinated against chicken pox, according to a Kaiser Permanente study in the December issue of the Pediatric Infectious Diseases Journal.

5 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

First patient treated in Carticept Medical's Cartiva SCI study

Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that the first patient has been treated in an international, multi-center study of the Company's Cartiva Synthetic Cartilage Implant (SCI). The study aims to determine the effectiveness of Cartiva SCI in comparison to arthrodesis (joint fusion), the current standard of care, for reducing the debilitating pain associated with osteoarthritis of the first metatarsophalangeal (MTP) joint.

4 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

PACS injection-record integration capabilities demonstrated at RSNA

Radiology imaging leader MEDRAD, Inc. demonstrated PACS injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Scientists attribute breast cancer decline to publicity surrounding WHI results

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

CAM314 randomized Phase 3 clinical trial results released

Study suggests sustained health risks linked to adverse childhood experiences

Discovery presents a vital step towards efficient treatment of vascular injuries

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

VAI expands to support annual research operation

Positive final data from Phase 2 study of ISTODAX presented

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Chicken pox vaccine also reduces risk of herpes zoster in children

Patients new to chronic disease medication face risk of medication discontinuation, finds study

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

First patient treated in Carticept Medical's Cartiva SCI study

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

New SPC3649 drug found effective in treating HCV infections

PACS injection-record integration capabilities demonstrated at RSNA

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in